ABSTRACT
Background: Accurate diagnosis of heart failure (HF) is essential for its proper management and logical drug therapy to reduce morbidity and mortality. On this perspective researcher are in search of a good biomarker as complementary to the clinical parameters to improve the performance of HF diagnosis. B-type natriuretic peptide (BNP) secreted by cardiac ventricles in HF has emerged as a new promising biomarker in this regard. Objective: To evaluate the performance of plasma BNP as a diagnostic biomarker in HF. Methods: In a cross sectional study 180 clinically suspected HF patients were selected. Their plasma BNP were measured and then subjected to echocardiogram. Patients were categorized as HF and without HF on the basis of echocardiogram and against this information the performance of plasma BNP of study subjects were evaluated as a diagnostic biomarker of HF considering 100 pg/ ml as its cut off point. Results: Sensitivity, specificity, accuracy, PPV, NPV, PLR and NLR of plasma BNP for diagnosis of HF found to be 88 %, 63.8 %, 77.2 %, 75.2 %, 81.0 %, 2.4 and 0.2 respectively. Conclusion: Plasma BNP concentration increases in HF. Based on 100 pg/ml as cut off point, plasma BNP shows good performance in diagnosis of HF.
ABSTRACT
Introduction: Pregnancy among adolescents is a health risk for the individual as well as the fetus. The main aim of this study is to examine the pregnancy complications and its outcome among adolescent women in Northern region (Rajshahi) of Bangladesh. Methods: The analysis is based on a part of faculty research; University of Rajshahi funded study on adolescent motherhood and pregnancy complications in the region, which involved a micro level survey of 400 adolescent conception aged 10-19 and indepth interviews with 37 adolescents who had experienced pregnancy wastage. The indicator of poor pregnancy outcomes analysed includes pregnancy or delivery complications and pregnancy wastage. Results: A striking finding is the higher proportions suffer pregnancy problems, especially in cases of early conception. In particular, younger adolescent aged under 20 years has been observed to have the highest proportions of delivery complications and pregnancy wastage due to insufficient intake foods and possible biological immaturity. Conclusion: Early teenage pregnancy and its effects pose very severe different pregnancy and delivery complications consequently wastage.
ABSTRACT
Background: Accurate diagnosis and clinical staging of heart failure (HF) is essential for its proper management and logical drug therapy to reduce morbidity and mortality. On this perspective researcher are in search of a good biomarker as complementary to the clinical parameters to improve the performance of HF diagnosis and its clinical staging. B-type natriuretic peptide (BNP) secreted by cardiac ventricles in HF has emerged as a new promising biomarker in this regard. Objective of the study was evaluation of plasma BNP concentration in relation to the severity of HF and its use as a biomarker for clinical staging of HF. Methods: In a cross sectional study 100 HF cases diagnosed by clinical parameters and echocardiography were enrolled and sub grouped into NYHA classes (I, II, II & IV) depending on clinical severity and functional limitations. Plasma BNP measured in all study subjects and summarized in each of these sub groups. Results: Median plasma BNP concentration in NYHA class-I, II, III & IV found to be 82.7, 267.2, 694.8 & 1530.4pg/ml respectively with progressive rising trend and at 95% CI level the plasma BNP in different sub groups were 64.5-112.7, 214.3-293.5, 626.4-902.4 & 1443.1-2384.4pg/ml respectively. Conclusion: Plasma BNP concentration increases progressively with increasing severity of HF to make it to be used for clinical staging of the disease. In mild, moderate and severe HF plasma BNP proposed to be 100-460, 460-1170 and >1170pg/ml respectively.
ABSTRACT
A case control study done to evaluate the Lipoprotein(a) [LP(a)] as a risk factor for CVD (cerebrovascular disease). 150 non-smokers, non-alcoholic subjects free from DM, renal disease, thyroid disease and liver disease were included in the study. Among them 120 were CVD cases and 30 were age and sex matched healthy control. Subjects were grouped as group-I (30, healthy control), Group-II (60, Hemorrhagic CVD) and group-III (60, Ischemic CVD). Fasting (12 hr) blood samples were collected from all subjects and in CVD cases samples were collected after 24 hr of attack. Lipid profile and LP(a) conc. were measured in all samples. Mean serum LP(a) conc. in Group-I, Group-II and Group-III were found to be 17.6 7.4 mg/dl, 31.9 15.6 mg/dl and 44.8 24.0 mg/dl respectively. Both the groups of CVD cases showed significantly higher level of serum LP(a) conc. compared to healthy control. CVD cases did not differ statistically in respect of their lipid profile when compared with control. Moreover the serum LP (a) conc. of CVD cases found to show no correlation with their lipid profile, suggesting the serum LP(a) conc. a possible independent risk factor for CVD.
Subject(s)
Adult , Aged , Cerebrovascular Disorders/blood , Female , Humans , Lipoprotein(a)/blood , Male , Middle Aged , Risk FactorsABSTRACT
A case-control study was done to evaluate the association of Lipoprotein(a)[LP(a)] with CVD (Cerebrovascular disease) and also to assess the implication of serum LP(a) concentration as a differentiating marker between ICVD (Ischemic CVD) & HCVD (Hemorrhagic CVD). 150 non-smokers, non-alcoholic subjects free from DM, renal disease, thyroid disease and liver disease were studied. Among them 120 were CVD cases and 30 were age & sex matched healthy control. Fasting (12 hr.) blood samples were collected from all subjects and in CVD cases samples were collected after 24 hr. of attack. Serum LP(a) concentration were measured in all samples. Mean serum LP(a) concentration in control, HCVD & ICVD were found to be 17.6 +/- 7.4 mg/dl, 31.9 +/- 15.6 mg/dl and 44.8 +/- 24.0 mg/dl respectively. Both HCVD & ICVD cases showed significantly higher level of serum LP(a) concentration compared to control. Moreover ICVD cases showed significantly higher level of serum LP(a) concentration compared to HCVD cases. The exquisite athero-thrombo-embolic potential of LP(a) explain its involvement with CVD but more with ICVD in comparison to HCVD; This finding apparently suggest the prospect of serum LP(a) concentration to be used as a promising laboratory maker to differentiate clinically the ICVD from HCVD following determination of cut-off value between ICVD & HCVD by broad based comprehensive study.